Contraindication vs warning comes down to what the label is telling the prescriber. A contraindication identifies a situation where a medicine should not be used. A warning flags a risk that needs assessment or follow-up. A precaution is a step that helps reduce harm, such as checking a blood test.
A warning can still lead a provider to decide against a medicine. A short contraindications list doesn't establish that someone qualifies.
Contraindication vs warning: sections 4 and 5
Prescribing information is the official document that explains a medicine's uses and risks. Its numbered sections have different jobs.
Under the federal labeling rule, section 4 covers situations where the risk clearly outweighs any possible treatment benefit. Section 5 covers important risks, limits on use, and steps to prevent or manage harm.
| Label term | Plain meaning | Where it appears |
|---|---|---|
| Contraindication | The medicine should not be used in the stated situation | Section 4 |
| Warning | A risk may affect whether or how the medicine is prescribed | Section 5 |
| Precaution | An assessment, monitoring step, or other measure may reduce harm | Section 5, alongside warnings |
The Food and Drug Administration (FDA) explains these categories in its October 2011 final guidance. The rule sets requirements; the guidance gives recommendations for applying them.
Why the distinction exists
The distinction separates a reason not to use a medicine from a risk requiring a closer look. Warnings and precautions share one section in modern labels. They aren't separate levels on a danger scale, and monitoring isn't always enough to make treatment appropriate.
Egrifta WR: active cancer and blood sugar
Egrifta WR is a branded tesamorelin medicine. The DailyMed label, marked “Revised: 3/2025,” makes the distinction concrete.
Section 4 lists active malignancy, meaning active cancer, as a contraindication. Section 5.4 addresses glucose intolerance, meaning difficulty keeping blood sugar in its usual range, and diabetes. It calls for checking blood sugar before treatment and periodic monitoring during treatment.
These entries answer different questions. Active cancer is a stated exclusion. Blood-sugar risk calls for assessment and can also change whether treatment makes sense.
The Egrifta label walkthrough covers the other sections. Its brand-specific directions don't establish directions for a compounded tesamorelin prescription.
Vyleesi: blood pressure shows the difference
Vyleesi is the branded bremelanotide medicine; bremelanotide is also called PT-141. Section 4 lists uncontrolled hypertension, meaning high blood pressure that isn't adequately controlled, and known cardiovascular disease, meaning heart or blood-vessel disease.
Section 5 explains why those questions matter: Vyleesi can temporarily raise blood pressure and lower heart rate. It calls for weighing heart risk and making sure blood pressure is well controlled before treatment and periodically during it. It also says Vyleesi isn't recommended for people at high risk of heart or blood-vessel disease.
That last statement matters even though it appears outside section 4. A warning is more than a suggestion to tolerate symptoms.
The RECONNECT trials, reported in Obstetrics & Gynecology in 2019, found more nausea, flushing, and headache with bremelanotide than placebo, an inactive comparison treatment. A side effect describes what may happen during treatment. A contraindication identifies when the medicine should not be used.
As of November 5, 2026, the day this article was written, the FDA-hosted Vyleesi label reads “Revised: 10/2026.” Section 8.2 now reports a 10-woman breast-milk study: the label calls the amount transferred clinically insignificant and says effects on breastfed infants are not expected, though they weren't directly evaluated. This also shows why a provider reads beyond sections 4 and 5.
The Vyleesi label walkthrough covers the broader label structure. A compounded PT-141 prescription is a separate preparation.
Three mistakes that change the meaning
“It isn't listed, so it must be safe.” A contraindications section lists known hazards, not every unanswered question. Missing language isn't proof of safety. Other sections may describe limited evidence or groups that weren't studied.
“A precaution is only for minor problems.” The useful question is what action the label describes. It might call for testing, avoiding another medicine, or reconsidering treatment. The heading alone doesn't measure the seriousness of the risk.
“Absolute means definite; warning means optional.” People use “absolute contraindication” to emphasize a do-not-use situation. Section 4 already serves that purpose. A warning still belongs in the prescribing decision; it isn't permission to ignore the issue.
Egrifta WR again: history changes the review
Egrifta WR's cancer warning shows why the details of a history matter. Section 4 says any preexisting cancer should be inactive, with its treatment complete, before treatment starts. Section 5.1 calls for weighing possible benefit against the risk of the cancer returning.
That differs from the active-cancer contraindication. A past diagnosis isn't enough information by itself: the provider needs the disease's current status and treatment history. Monitoring doesn't turn an active-cancer exclusion into a manageable warning.
The early Falutz trial (New England Journal of Medicine, 2007) compared daily tesamorelin with placebo for 26 weeks in 412 adults with HIV, a virus that weakens immune defenses, and excess abdominal fat. Those findings describe a particular group, rather than everyone considering tesamorelin.
The same care applies when reading about compounded tesamorelin. A brand label can inform the safety conversation without establishing another preparation's results or directions.
A licensed U.S. compounding pharmacy dispenses tesamorelin and PT-141 prescribed through Promise. These are compounded medications, which are different from the FDA-approved Egrifta WR and Vyleesi: the formulations offered here are not FDA-approved. The FDA's compounding explanation describes that distinction. A licensed provider may still prescribe — that decision is between you and your doctor.
Related terms to keep straight
A boxed warning puts a particularly serious concern at the top of a label. It can highlight a contraindication or another warning; it isn't a synonym for either section.
Off-label use describes a use outside a reviewed product's stated labeling. That is a different question from whether the label identifies a contraindication.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The review connects the label's words with the person's actual history, medicines, and treatment goals.
